Corcept Therapeutics Incorporated (CORT) Covered Calls

Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company leading the field of cortisol modulation. The company develops proprietary medications to treat severe endocrinologic, oncologic, and metabolic disorders. In 2026, Corcept is focused on its transition into a multi-product oncology player following the landmark FDA approval of relacorilant for platinum-resistant ovarian cancer.

You can sell covered calls on Corcept Therapeutics Incorporated to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CORT (prices last updated Thu 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Corcept Therapeutics Incorporated (CORT) is the world leader in glucocorticoid receptor (GR) antagonism. The company built its foundation on Korlym, the first FDA-approved treatment for endogenous Cushing's syndrome. Corcept’s 2026 strategy is defined by its transition from a single-product company to a multi-indication oncology and endocrinology powerhouse. By focusing on selective cortisol modulators, Corcept aims to mitigate the side effects associated with older, non-selective treatments while unlocking new therapeutic pathways in cancer and metabolic disease.

Core Business and Products

The company revenue is anchored by Korlym (mifepristone), which continues to see strong demand in the Cushing’s syndrome market. However, the standout development in 2026 is the commercial launch of Lifyorli (relacorilant). Approved in March 2026 for platinum-resistant ovarian cancer, Lifyorli works by enhancing chemotherapy sensitivity, showing a 35% reduction in the risk of death in pivotal trials. Corcept also manages a robust pipeline including dazucorilant for ALS and miricorilant for MASH (liver disease), both of which are expected to yield critical Phase 2b and Phase 3 data by the end of 2026.

Competitive Landscape

1. Jazz Pharmaceuticals plc is a primary competitor in the orphan drug and specialty oncology space, vying for market share in complex therapeutic areas that require high-touch specialty pharmacy support.
2. Supernus Pharmaceuticals, Inc. competes for investor capital in the specialty CNS and metabolic segments, representing another highly liquid and optionable mid-cap biotech peer.
3. Exelixis, Inc. is a major rival in the oncology market, particularly as Corcept expands its portfolio of small-molecule inhibitors designed to enhance standard-of-care cancer treatments.
4. Perrigo Company plc competes in the broader "diversified medical" sector; while its focus is different, it serves as a key optionable benchmark for mid-cap pharmaceutical profitability.
5. Nektar Therapeutics is a competitor in the immuno-oncology and specialty biotech space, often trading in the same volatility clusters as Corcept during major clinical data readouts.

Strategic Outlook and Innovation

The strategic focus for Corcept in 2026 is "Growth Through Diversification." Following record-breaking demand for its medications in 2025, the company has issued bullish 2026 revenue guidance of $900 million to $1 billion. Management is prioritizing the rollout of Lifyorli, which has already been added to the NCCN Guidelines as a "preferred regimen" for ovarian cancer. Corcept is also navigating a legal win/loss landscape; while it continues to appeal patent rulings regarding generic competition for Korlym, its shift toward proprietary, next-generation modulators like relacorilant provides a significant defensive "patent wall" through the early 2030s.

Innovation at Corcept is currently centered on "Precision Cortisol Modulation." In 2026, the company is utilizing data from its MOMENTUM and CATALYST trials to identify specific patient sub-populations with "resistant diabetes" who may benefit from GR antagonism. Furthermore, Corcept is pioneering the use of AI-enhanced biomarker identification to predict which solid tumors are most likely to express high levels of the glucocorticoid receptor, allowing for more targeted oncology trials. By doubling its R&D investment in 2026 to over $250 million, Corcept aims to prove that cortisol modulation is a critical, yet previously underutilized, lever in treating the world’s most difficult-to-treat diseases.

Want more examples? CORN Covered Calls | CORZ Covered Calls